Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) Journal Article
| Authors: | Mesa, R. A.; Verstovsek, S.; Cervantes, F.; Barosi, G.; Reilly, J. T.; Dupriez, B.; Levine, R.; Le Bousse-Kerdiles, M. C.; Wadleigh, M.; Campbell, P. J.; Silver, R. T.; Vannucchi, A. M.; Deeg, H. J.; Gisslinger, H.; Thomas, D.; Odenike, O.; Solberg, L. A.; Gotlib, J.; Hexner, E.; Nimer, S. D.; Kantarjian, H.; Orazi, A.; Vardiman, J. W.; Thiele, J.; Tefferi, A. |
| Article Title: | Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT) |
| Abstract: | The International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) is comprised of hematologists, hematopathologists, and laboratory scientists and its main goal is to provide a forum for scientific exchange and collaboration. During its first general meeting in April 2006, the IWG-MRT established uniform treatment response criteria for chronic idiopathic myelofibrosis (CIMF); also known as agnogenic myeloid metaplasia (AMM), myelofibrosis with myeloid metaplasia (MMM), and many other names in the hematologic literature. This document summarizes the proceedings from the second meeting of the IWG-MRT, in November 2006, where the group discussed and agreed to standardize the nomenclature referring to CIMF: (i) the term primary myelofibrosis (PMF) was chosen over several other designations including CIMF, AMM, and MMM, (ii) myelofibrosis that develops in the setting of either polycythemia vera (PV) or essential thrombocythemia (ET) will be referred to as post-PV MF and post-ET MF, respectively, and (iii) "leukemic" transformation will be recognized as blast phase disease (PMF-BP, post-PV/ET MF in blast phase). © 2007 Elsevier Ltd. All rights reserved. |
| Keywords: | treatment response; myeloproliferative disorders; myelofibrosis; metaplasia; gene mutation; myeloid metaplasia; primary myelofibrosis; consensus; bone marrow; spleen; histology; stem cell; cell transformation, neoplastic; chronic disease; standardization; cytokine; blood; research; organization; nomenclature; polycythemia vera; paramedical personnel; blast crisis; terminology; thrombocythemia, hemorrhagic; chronic idiopathic myelofibrosis; international working group for myelofibrosis research and treatment; iwg-mrt; myelofibrosis with myeloid metaplasia; blast phase primary myelofibrosis; hematologist; hematopathologist; laboratory scientist; polycythemia vera myelofibrosis; post essential thrombocytopenia myelofibrosis |
| Journal Title: | Leukemia Research |
| Volume: | 31 |
| Issue: | 6 |
| ISSN: | 0145-2126 |
| Publisher: | Elsevier Ltd |
| Date Published: | 2007-06-01 |
| Start Page: | 737 |
| End Page: | 740 |
| Language: | English |
| DOI: | 10.1016/j.leukres.2006.12.002 |
| PUBMED: | 17210175 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 65" - "Export Date: 17 November 2011" - "CODEN: LERED" - "Source: Scopus" |
